An open-label study of the long term tolerability and safety of atomoxetine in treating the inattention, impulsivity and hyperactivity in children with fetal-alcohol syndrome or effects

Trial Profile

An open-label study of the long term tolerability and safety of atomoxetine in treating the inattention, impulsivity and hyperactivity in children with fetal-alcohol syndrome or effects

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Status changed from recruiting to completed.
    • 20 May 2010 Planned end date changed from 1 Dec 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 27 Jul 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top